Impact of diabetes on mortality in patients with myocardial infarction and left ventricular dysfunction

Alvaro M. Murcia, Charles H. Hennekens, Gervasio A. Lamas, Manuel Jiménez-Navarro, Jean L. Rouleau, Greg C. Flaker, Steven Goldman, Hicham Skali, Eugene Braunwald, Marc A. Pfeffer

Research output: Contribution to journalArticle

105 Citations (Scopus)

Abstract

Background: Diabetes is a major risk factor for developing coronary heart disease. In patients with diabetes who survived myocardial infarction (MI), less is known about subsequent morbidity and mortality. We evaluated the effects of diabetes in post-MI patients with left ventricular dysfunction on cardiovascular events and death. Methods: The Survival and Ventricular Enlargement, a randomized, double-blind, placebo-controlled multicenter trial, evaluated the efficacy of captopril vs placebo in 2231 patients following acute MI with left ventricular dysfunction defined as an ejection fraction less than or equal to 40%. Patients were randomly assigned to captopril or placebo 3 to 16 days following MI and were followed up for 2 to 5 years (mean, 3.5 years). Results: Among the 2231, 496 (22.2%) were patients with a history of diabetes, of which 168 (33.9%) were treated with insulin. Patients with diabetes were significantly older; more likely to be women; have a history of prior MI or hypertension; be obese or manifest Killip class II or greater; and have higher systolic blood pressure, pulse pressure, and heart rate, as well as lower ejection fraction. During follow-up, 31.3% of patients with diabetes and 20.1% of nondiabetic patients died (P<.001). Furthermore, 50% of the patients with diabetes had at least 1 major cardiovascular event compared with 32.3% among the nondiabetic patients (P<.001). In multivariate analysis that adjusted for all significant differences in baseline characteristics, patients with diabetes had a 39% higher total mortality (P=.001) and 49% more cardiovascular events (P=.001). Among the patients with diabetes, baseline insulin treatment was associated with a greater risk of death (41.1% vs 26.2%; P=.001) and cardiovascular events (58.3% vs 45.7%; P=.008). Conclusions: In patients who survived MI with left ventricular dysfunction, diabetes increased risk of death from all causes even after controlling for differences in other risk factors. Patients with diabetes treated with insulin have a particularly higher mortality risk. Patients with diabetes who survived MI with left ventricular dysfunction, in particular those receiving insulin, are at high risk of subsequent mortality and cardiovascular events and thus require intensive risk factor modification, as well as evaluation for novel therapies.

Original languageEnglish (US)
Pages (from-to)2273-2279
Number of pages7
JournalArchives of Internal Medicine
Volume164
Issue number20
DOIs
StatePublished - Nov 8 2004
Externally publishedYes

Fingerprint

Left Ventricular Dysfunction
Myocardial Infarction
Mortality
Insulin
Captopril
Placebos
Heart Rate
Blood Pressure
Hypertension
Multicenter Studies
Coronary Disease
Cause of Death

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Murcia, A. M., Hennekens, C. H., Lamas, G. A., Jiménez-Navarro, M., Rouleau, J. L., Flaker, G. C., ... Pfeffer, M. A. (2004). Impact of diabetes on mortality in patients with myocardial infarction and left ventricular dysfunction. Archives of Internal Medicine, 164(20), 2273-2279. https://doi.org/10.1001/archinte.164.20.2273

Impact of diabetes on mortality in patients with myocardial infarction and left ventricular dysfunction. / Murcia, Alvaro M.; Hennekens, Charles H.; Lamas, Gervasio A.; Jiménez-Navarro, Manuel; Rouleau, Jean L.; Flaker, Greg C.; Goldman, Steven; Skali, Hicham; Braunwald, Eugene; Pfeffer, Marc A.

In: Archives of Internal Medicine, Vol. 164, No. 20, 08.11.2004, p. 2273-2279.

Research output: Contribution to journalArticle

Murcia, AM, Hennekens, CH, Lamas, GA, Jiménez-Navarro, M, Rouleau, JL, Flaker, GC, Goldman, S, Skali, H, Braunwald, E & Pfeffer, MA 2004, 'Impact of diabetes on mortality in patients with myocardial infarction and left ventricular dysfunction', Archives of Internal Medicine, vol. 164, no. 20, pp. 2273-2279. https://doi.org/10.1001/archinte.164.20.2273
Murcia AM, Hennekens CH, Lamas GA, Jiménez-Navarro M, Rouleau JL, Flaker GC et al. Impact of diabetes on mortality in patients with myocardial infarction and left ventricular dysfunction. Archives of Internal Medicine. 2004 Nov 8;164(20):2273-2279. https://doi.org/10.1001/archinte.164.20.2273
Murcia, Alvaro M. ; Hennekens, Charles H. ; Lamas, Gervasio A. ; Jiménez-Navarro, Manuel ; Rouleau, Jean L. ; Flaker, Greg C. ; Goldman, Steven ; Skali, Hicham ; Braunwald, Eugene ; Pfeffer, Marc A. / Impact of diabetes on mortality in patients with myocardial infarction and left ventricular dysfunction. In: Archives of Internal Medicine. 2004 ; Vol. 164, No. 20. pp. 2273-2279.
@article{920d25f52c42466db8ff314445fb41a7,
title = "Impact of diabetes on mortality in patients with myocardial infarction and left ventricular dysfunction",
abstract = "Background: Diabetes is a major risk factor for developing coronary heart disease. In patients with diabetes who survived myocardial infarction (MI), less is known about subsequent morbidity and mortality. We evaluated the effects of diabetes in post-MI patients with left ventricular dysfunction on cardiovascular events and death. Methods: The Survival and Ventricular Enlargement, a randomized, double-blind, placebo-controlled multicenter trial, evaluated the efficacy of captopril vs placebo in 2231 patients following acute MI with left ventricular dysfunction defined as an ejection fraction less than or equal to 40{\%}. Patients were randomly assigned to captopril or placebo 3 to 16 days following MI and were followed up for 2 to 5 years (mean, 3.5 years). Results: Among the 2231, 496 (22.2{\%}) were patients with a history of diabetes, of which 168 (33.9{\%}) were treated with insulin. Patients with diabetes were significantly older; more likely to be women; have a history of prior MI or hypertension; be obese or manifest Killip class II or greater; and have higher systolic blood pressure, pulse pressure, and heart rate, as well as lower ejection fraction. During follow-up, 31.3{\%} of patients with diabetes and 20.1{\%} of nondiabetic patients died (P<.001). Furthermore, 50{\%} of the patients with diabetes had at least 1 major cardiovascular event compared with 32.3{\%} among the nondiabetic patients (P<.001). In multivariate analysis that adjusted for all significant differences in baseline characteristics, patients with diabetes had a 39{\%} higher total mortality (P=.001) and 49{\%} more cardiovascular events (P=.001). Among the patients with diabetes, baseline insulin treatment was associated with a greater risk of death (41.1{\%} vs 26.2{\%}; P=.001) and cardiovascular events (58.3{\%} vs 45.7{\%}; P=.008). Conclusions: In patients who survived MI with left ventricular dysfunction, diabetes increased risk of death from all causes even after controlling for differences in other risk factors. Patients with diabetes treated with insulin have a particularly higher mortality risk. Patients with diabetes who survived MI with left ventricular dysfunction, in particular those receiving insulin, are at high risk of subsequent mortality and cardiovascular events and thus require intensive risk factor modification, as well as evaluation for novel therapies.",
author = "Murcia, {Alvaro M.} and Hennekens, {Charles H.} and Lamas, {Gervasio A.} and Manuel Jim{\'e}nez-Navarro and Rouleau, {Jean L.} and Flaker, {Greg C.} and Steven Goldman and Hicham Skali and Eugene Braunwald and Pfeffer, {Marc A.}",
year = "2004",
month = "11",
day = "8",
doi = "10.1001/archinte.164.20.2273",
language = "English (US)",
volume = "164",
pages = "2273--2279",
journal = "JAMA Internal Medicine",
issn = "2168-6106",
publisher = "American Medical Association",
number = "20",

}

TY - JOUR

T1 - Impact of diabetes on mortality in patients with myocardial infarction and left ventricular dysfunction

AU - Murcia, Alvaro M.

AU - Hennekens, Charles H.

AU - Lamas, Gervasio A.

AU - Jiménez-Navarro, Manuel

AU - Rouleau, Jean L.

AU - Flaker, Greg C.

AU - Goldman, Steven

AU - Skali, Hicham

AU - Braunwald, Eugene

AU - Pfeffer, Marc A.

PY - 2004/11/8

Y1 - 2004/11/8

N2 - Background: Diabetes is a major risk factor for developing coronary heart disease. In patients with diabetes who survived myocardial infarction (MI), less is known about subsequent morbidity and mortality. We evaluated the effects of diabetes in post-MI patients with left ventricular dysfunction on cardiovascular events and death. Methods: The Survival and Ventricular Enlargement, a randomized, double-blind, placebo-controlled multicenter trial, evaluated the efficacy of captopril vs placebo in 2231 patients following acute MI with left ventricular dysfunction defined as an ejection fraction less than or equal to 40%. Patients were randomly assigned to captopril or placebo 3 to 16 days following MI and were followed up for 2 to 5 years (mean, 3.5 years). Results: Among the 2231, 496 (22.2%) were patients with a history of diabetes, of which 168 (33.9%) were treated with insulin. Patients with diabetes were significantly older; more likely to be women; have a history of prior MI or hypertension; be obese or manifest Killip class II or greater; and have higher systolic blood pressure, pulse pressure, and heart rate, as well as lower ejection fraction. During follow-up, 31.3% of patients with diabetes and 20.1% of nondiabetic patients died (P<.001). Furthermore, 50% of the patients with diabetes had at least 1 major cardiovascular event compared with 32.3% among the nondiabetic patients (P<.001). In multivariate analysis that adjusted for all significant differences in baseline characteristics, patients with diabetes had a 39% higher total mortality (P=.001) and 49% more cardiovascular events (P=.001). Among the patients with diabetes, baseline insulin treatment was associated with a greater risk of death (41.1% vs 26.2%; P=.001) and cardiovascular events (58.3% vs 45.7%; P=.008). Conclusions: In patients who survived MI with left ventricular dysfunction, diabetes increased risk of death from all causes even after controlling for differences in other risk factors. Patients with diabetes treated with insulin have a particularly higher mortality risk. Patients with diabetes who survived MI with left ventricular dysfunction, in particular those receiving insulin, are at high risk of subsequent mortality and cardiovascular events and thus require intensive risk factor modification, as well as evaluation for novel therapies.

AB - Background: Diabetes is a major risk factor for developing coronary heart disease. In patients with diabetes who survived myocardial infarction (MI), less is known about subsequent morbidity and mortality. We evaluated the effects of diabetes in post-MI patients with left ventricular dysfunction on cardiovascular events and death. Methods: The Survival and Ventricular Enlargement, a randomized, double-blind, placebo-controlled multicenter trial, evaluated the efficacy of captopril vs placebo in 2231 patients following acute MI with left ventricular dysfunction defined as an ejection fraction less than or equal to 40%. Patients were randomly assigned to captopril or placebo 3 to 16 days following MI and were followed up for 2 to 5 years (mean, 3.5 years). Results: Among the 2231, 496 (22.2%) were patients with a history of diabetes, of which 168 (33.9%) were treated with insulin. Patients with diabetes were significantly older; more likely to be women; have a history of prior MI or hypertension; be obese or manifest Killip class II or greater; and have higher systolic blood pressure, pulse pressure, and heart rate, as well as lower ejection fraction. During follow-up, 31.3% of patients with diabetes and 20.1% of nondiabetic patients died (P<.001). Furthermore, 50% of the patients with diabetes had at least 1 major cardiovascular event compared with 32.3% among the nondiabetic patients (P<.001). In multivariate analysis that adjusted for all significant differences in baseline characteristics, patients with diabetes had a 39% higher total mortality (P=.001) and 49% more cardiovascular events (P=.001). Among the patients with diabetes, baseline insulin treatment was associated with a greater risk of death (41.1% vs 26.2%; P=.001) and cardiovascular events (58.3% vs 45.7%; P=.008). Conclusions: In patients who survived MI with left ventricular dysfunction, diabetes increased risk of death from all causes even after controlling for differences in other risk factors. Patients with diabetes treated with insulin have a particularly higher mortality risk. Patients with diabetes who survived MI with left ventricular dysfunction, in particular those receiving insulin, are at high risk of subsequent mortality and cardiovascular events and thus require intensive risk factor modification, as well as evaluation for novel therapies.

UR - http://www.scopus.com/inward/record.url?scp=7544230150&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=7544230150&partnerID=8YFLogxK

U2 - 10.1001/archinte.164.20.2273

DO - 10.1001/archinte.164.20.2273

M3 - Article

C2 - 15534166

AN - SCOPUS:7544230150

VL - 164

SP - 2273

EP - 2279

JO - JAMA Internal Medicine

JF - JAMA Internal Medicine

SN - 2168-6106

IS - 20

ER -